What Iruxol mono Treats: Main Uses and Benefits

Iruxol mono is applied across domains where additional symptomatic support is needed by specifically addressing the symptoms related to the presence of dead, non-viable tissue (necrosis or slough) in wounds. This treatment is commonly used across conditions involving episodic or fluctuating manifestations, such as chronic ulcers or complex wounds. This debridement is considered relevant for easing symptoms associated with these chronic conditions by supporting the removal of the dead tissue.

It is applied in clinical settings that involve acute or unstable symptom patterns, helping to manage symptoms that interfere with daily comfort. In these situations, the medication offers symptomatic relief that helps patients cope more steadily by supporting the transition to a clean wound bed.

“The supportive action assists with maintaining functional stability in the affected area.”

This supportive relief contributes to easing the overall symptom load and is particularly relevant when symptoms create noticeable physiological strain.

Quick Fact: Relevant for Wounds with Dead Tissue

Eligibility Profile

Populations for whom use is allowed (as stated in label):

• Adults requiring the enzymatic debridement of necrotising wounds, including leg ulcers and decubital ulcers.

Populations for whom use is contraindicated:

• Patients with known hypersensitivity or allergy to clostridiopeptidase A (collagenase) or any of the ointment's inactive ingredients.

---

Eligibility Restrictions and Caution

Age-related eligibility rules:

• Adults (General Population): Use is established and indicated.
• Pediatric Patients: Safety and effectiveness have not been established in this age group by regulatory authorities.

Condition-specific eligibility rules:

• Patients who are diabetic and present with dry gangrene in the wound area require conditional use and special caution to avoid converting the wound to moist gangrene.

Pregnancy and lactation eligibility status:

• Pregnancy (First Three Months): Restricted; the medicine should only be administered when strictly indicated by a physician.
• Pregnancy (After Three Months) and Lactation: Use is documented as generally acceptable due to the unlikelihood of systemic absorption.

---

Eligibility Classifications (Summary): Official documents define eligibility through patient status. The main exclusion is the absolute contraindication of hypersensitivity to the ingredients. Use is deemed conditional during early pregnancy and in diabetic patients with dry gangrene. Regulatory labeling explicitly states that safety and effectiveness have not been established in pediatric patients.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Iruxol mono (collagenase ointment) primarily through local constraints at the site of application. The active ingredient, a proteolytic enzyme, has negligible systemic absorption, meaning the product has no documented systemic interactions involving CYP enzymes, drug transporters, or alterations to the plasma concentration of co-administered systemic medicines.

Interactions are categorized by the risk of inhibition or inactivation of the collagenase enzyme's activity on the wound bed. Co-administration of certain agents is explicitly restricted to preserve the ointment's function:

---

Prohibited Local Co-Administration

Product Category	Specific Agents	Interaction Outcome
Enzyme Inhibitors	Antiseptics, Heavy metals, Detergents, Soaps	Documented to chemically inhibit enzyme activity.
Local Antibiotics	Tyrothricin, Gramicidin, Tetracyclines	Should not be used locally with the ointment.

---

These restrictions are based on the potential for chemical interference, which prevents the enzyme from functioning correctly. Regulatory labeling notes that products containing silver or silver sulfadiazine can be used with Iruxol mono without affecting the collagenase enzyme activity. No specific interactions are documented concerning food, drink, or mandatory timing separation from other medicines.

Direct Enzymatic Digestion of Necrotic Collagen

The active ingredient, collagenase (Clostridiopeptidase A), acts as an exogenous metalloproteinase that directly engages its target: denatured collagen. This enzyme initiates selective proteolysis, a chemical process where water is used to split the peptide bonds within the collagen fibers that anchor dead tissue ( eschar and slough) to the wound base. This primary molecular action leads directly to the enzymatic tissue liquefaction of the necrotic debris.

---

Causal Cascade: Structural Clearance and Wound Bed Preparation

The localized digestion of the collagen scaffold triggers a crucial mechanistic cascade, converting the rigid, non-viable tissue into soluble fragments. This physical clearance is a profound physiological modulation, which systematically breaks down and removes the necrotic material. The mechanism exhibits natural selectivity, preferentially targeting the unprotected, damaged collagen over the healthy collagen in viable tissue, thereby providing the necessary physiological environment for subsequent endogenous processes.

---

Limitations: Environmental Constraints on Activity

The enzyme's activity is chemically vulnerable to its environment, a key mechanistic constraint. The proteolytic function requires specific conditions and is inhibited by external factors like heavy metal ions and certain oxidizing antiseptics (e.g., silver or iodine compounds), which can interfere with the enzyme's structural integrity or its essential cofactors. The chemical interactions directly govern the sustained functional capacity of the mechanism. This process provides an unobstructed biological surface, which is a physiological prerequisite for the engagement of natural cellular repair mechanisms.

The administration of the collagenase-based ointment, Iruxol mono, follows a specific protocol for its topical application to the wound surface. The standard dosing regimen specifies the application of a thin layer, roughly 2 mm thick, which must achieve close contact with the entire area requiring treatment.

The usual application frequency is once daily; however, application may be increased to twice daily if the wound is heavily soiled or the dressing requires frequent changing.

Prior to application, the wound site must often be prepared. The collagenase enzyme is active within a pH range of 6 to 8, and dry wounds must be moistened, typically using physiological saline (0.9% NaCl), to maintain this optimal environment. Crucially, the local use of certain substances must be strictly avoided, as the enzyme's function is inhibited by heavy metal ions (found in some antiseptics) as well as soaps, detergents, and certain local antibiotics.

The duration of use is determined by the wound's status. Treatment is maintained until the area is clean and the formation of granulation tissue is established. If no reduction in non-viable tissue is observed within 14 days of commencement, the use should be discontinued. For specific populations, the safety and effectiveness have not been established in pediatric patients.

Evidence for Use in Wounds Requiring Debridement

Clinical research, including Randomized Controlled Trials (RCTs) and systematic reviews, has investigated the agent's effect on the clearance of dead tissue (necrotic tissue, eschar, and slough) from chronic dermal ulcers and burns. Studies explored the agent's application in chronic wound contexts, such as pressure injuries, venous ulcers, and diabetic foot ulcers. Comparisons were often made against placebo or other debridement methods. The primary focus of the trials was on debridement and wound bed preparation outcomes. Researchers monitored the rate of tissue clearance and the time required to meet the specific goal of a clean wound bed.

---

Long-Term Outcomes and Research Gaps

Most published research explores short-term symptom changes, focusing on the acute debridement phase which typically lasts between two and six weeks. Longer follow-up durations were limited, meaning that complete and sustained wound closure and long-term effects are not fully established by the trials. Data for long-term outcomes and certain patient subgroups remain limited, and independent reviews suggest that certainty remains low due to methodological limitations in some of the underlying primary research.

---

Evidence in Specific Patient Groups

Research examined the agent in general adult populations with chronic wounds. Studies were conducted on older adults, particularly those with pressure injuries or venous issues. Research also examined the product in diabetic subjects presenting with non-ischemic diabetic foot ulcers. Limited data are available for certain specific groups, such as pediatric patients outside of smaller-area burns, meaning results apply only to the populations studied.

Key Studies & References

1. Comparison of healing effectiveness of different debridement approaches for diabetic foot ulcers: a network meta-analysis of randomized controlled trials
2. Hyaluronic Acid/Collagenase Ointment in the Treatment of Chronic Hard-to-Heal Wounds: An Observational and Retrospective Study

Common questions about Iruxol mono (FAQ)

---

Q: What is Iruxol mono and what is it used for?

A: Iruxol mono is an ointment that contains the active ingredients clostridiopeptidase A (a collagenase enzyme) and other associated protease enzymes. It is used to remove dead or necrotic tissue (a process called debridement) from various types of wounds, which include:

• Leg ulcers (e.g., varicose ulcers)
• Diabetic ulcers
• Pressure sores (bedsores)

By cleansing the wound and removing the dead tissue, the ointment helps to speed up the process of wound healing.

---

Q: How does Iruxol mono work?

A: The active ingredients in the ointment are enzymes called collagenase and proteases. These enzymes work together to break down the protein components of the dead or necrotic tissue in the wound. The collagenase enzyme specifically targets and breaks down collagen fibers, which helps to loosen and remove the damaged material. This selective action cleans the wound bed, allowing new, healthy tissue to form and the wound to heal.

---

Q: What should I know before using Iruxol mono?

A: You should not use Iruxol mono if you are allergic to clostridiopeptidase A, protease enzymes, or any of the other ingredients in the ointment. You should also take special care and consult a healthcare professional before use if:

• You are diabetic and the wound contains dry gangrenous material.
• You are in the first three months of pregnancy.

---

Q: Can I use other products on the wound at the same time as Iruxol mono?

A: No, you should not use other products on the wound area that might interfere with the medicine's activity. The effectiveness of the enzymes in Iruxol mono can be inhibited or reduced by the presence of certain substances. You must avoid using it at the same time as:

• Certain antibiotics (specifically tyrothricin, gramicidin, and tetracyclines)
• Antiseptics
• Heavy metals
• Detergents and soaps

Always inform your doctor or pharmacist about all other medicines or products you are using.

---

Q: How is Iruxol mono applied?

A: The ointment is for skin use only, and you must avoid contact with the eyes and mouth.

1. A layer of approximately 2 mm of the ointment should be applied either directly to the wound or to a dressing which is then placed on the wound.
2. You must ensure the ointment is in close contact with the wound surface.
3. Wound moisture is essential for the medicine to work. If the wound is dry, or becomes dry, it should be moistened with a physiological saline solution (0.9% sodium chloride) or another tissue-tolerant solution before applying the ointment. Dry or hard crusts may need to be softened first with a moist dressing.
4. The application is usually done once a day, though a healthcare professional may occasionally recommend twice-daily use.

Treatment is typically stopped once the entire wound surface is clean and the dead tissue is removed.

---

Q: What are the common side effects of Iruxol mono?

A: Iruxol mono is generally well-tolerated. The most common side effects reported are reactions at the application site, which may include:

• Local pain
• Pruritus (itching)
• Burning sensation
• Erythema (redness)

If you experience any side effects, including those not listed, you should talk to your doctor or pharmacist.

---

Q: Can Iruxol mono be used during pregnancy or while breastfeeding?

A: You should not use Iruxol mono if you are or think you may be less than three months pregnant, unless a doctor has strictly told you to do so. The ointment is considered safe to use if you are more than three months pregnant and while breastfeeding. As a general precaution, it is always best to ask your doctor or pharmacist for advice before using any medicine during pregnancy or breastfeeding.

How to Store and Dispose of Iruxol mono

The storage and disposal of Iruxol mono (collagenase) ointment must adhere strictly to the conditions specified in official regulatory labeling.

---

Storage Conditions

Requirement	Official Instruction
Temperature	Store below 25°C (77°F).
Children	Keep out of the reach and sight of children.
Stability	Do not use the ointment after the labeled expiry date.

The required storage temperature is vital for preserving the stability of the collagenase enzyme, which gives the product a stated shelf-life of three years.

---

Disposal Instructions

Unused or expired Iruxol mono must not be disposed of in general household waste or flushed down wastewater. Patients are instructed to consult a pharmacist or local authority for the correct method of discarding pharmaceutical waste.